Daniela Dal Molim Ghisleni

Daniela Dal Molim Ghisleni

Auto-generated profile, based on publicly available information

Daniela Dal Molim Ghisleni

Departamento de Farmácia, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo, SP, Brasil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2018 in Journal of Pharmaceutical Innovation
Verified
Journal Article
Closed access
PDF file
ABAdriana Bugno
Adriana Bugno
AAAdriana Aparecida Buzzo Almodovar
Adriana Aparecida Buzzo Almodovar
DSDeborah Pita Sanches Saes
Deborah Pita Sanches Saes
RARajendra Awasthi
Rajendra Awasthi
DGDaniela Dal Molim Ghisleni
Daniela Dal Molim Ghisleni
Terezinha de Jesus Andreoli PintoTerezinha de Jesus Andreoli Pinto
Terezinha de Jesus Andreoli Pinto

13 June 2024 in Revista Do Instituto Adolfo Lutz
Verified
Journal Article
Open access
PDF file
EHEllen Hilinski
Ellen Hilinski
DGDaniela Dal Molim Ghisleni
Daniela Dal Molim Ghisleni
CUCarla Lilian de Agostini Utescher
Carla Lilian de Agostini Utescher
WQWagner Quintilio
Wagner Quintilio
AAAdriana Aparecida Buzzo Almodovar
Adriana Aparecida Buzzo Almodovar
Terezinha de Jesus Andreoli PintoTerezinha de Jesus Andreoli Pinto
Terezinha de Jesus Andreoli Pinto
Endotoxin contamination is a threat to the safety of pharmaceutical products, especially parenteral drugs. Any sterile and/or pyrogen-free pharmaceutical product requires regulatory specifications to ensure safe patient use. This study covers theperformance evaluation study of an endotoxinquantitat ion commercial kit by recombinant Factor C (rFC),Endozyme II® Go, for 0.9% sodium chloride injection. The samples were spiked with endotoxin solutions between 0.0005 and 10 EU/mL and tested by the rFC kit to evaluate precision, accuracy, detection and quantification limits, linearity, and robustness. Each of the six points was assayed at least five times. The relative standard deviation for precision testing ranged from 1.9 to 8.3%. The recovery accuracy values of endotoxin were between 61% and 125% for the range from 0.005 to 10 EU/mL. The results demonstrated that the rFC method allows endotoxin quantification with accuracy, precision, specificity, and linearity for the range of 0.005 and 10 EU/mL for 0.9% sodium chloride injection. A contaminação por endotoxinas é uma ameaça à segurança dos produtos farmacêuticos, especialmente dos medicamentos parenterais. Qualquer produto farmacêutico estéril e/ou livre de pirogênios requer especificações regulatórias para garantir a segurança de uso para o paciente. Este estudo abrange o estudo de avaliação de desempenho empregando o kit comercial Endozyme II® Go para quantificação de endotoxina, por Fator C recombinante (FCr), em amostras de cloreto de sódio 0,9% para uso parenteral. As amostras foram fortificadas com cinco concentrações distintas de soluções de endotoxina na faixa entre 0,0005 e 10 UE/mL. Cada um dos cinco níveis foi testado pelo menos cinco vezes para avaliação dos critérios de precisão, exatidão, limites de detecção e quantificação, linearidade e robustez. O desvio padrão relativo para os testes de precisão variou de 1,9 a 8,3%. Os valores de recuperação de endotoxina para o parâmetro exatidão estiveram compreendidos entre 61% e 125%. Os resultados demonstraram que o método por FCr permite a quantificação de endotoxinas com exatidão, precisão, especificidade e linearidade para a faixa de 0,005 e 10 UE/mL em amostras de cloreto de sódio 0,9% para uso parenteral.

12 December 2025 in Vigilância Sanitária Em Debate: Sociedade, Ciência & Tecnologia
Verified
Journal Article
Open access
PDF file
EHEllen Gameiro Hilinski
Ellen Gameiro Hilinski
DGDaniela Dal Molim Ghisleni
Daniela Dal Molim Ghisleni
CUCarla Lilian De Agostini Utescher
Carla Lilian De Agostini Utescher
WQWagner Quintilio
Wagner Quintilio
Terezinha de Jesus Andreoli PintoTerezinha de Jesus Andreoli Pinto
Terezinha de Jesus Andreoli Pinto
Introduction: Endotoxin contamination poses a significant risk to the safety of pharmaceutical products, particularly those administered parenterally. Ensuring patient safety requires strict adherence to the regulatory standards for sterile and pyrogen-free pharmaceutical formulations. Objective: This study aimed to evaluate the feasibility of using the Recombinant Factor C (rFC) method, specifically Endolisa®, for detecting bacterial endotoxins in hyperimmune sera (pentavalent antibothropic, anti-rabies, and tetanus antitoxin). Method: Samples were spiked with endotoxin solutions at concentrations ranging from 0.05 to 10 EU/mL and analyzed using the rFC kit. The key performance parameters were thoroughly evaluated, such as specificity, detection and quantification limits, precision, accuracy, and linearity. Each concentration was tested a minimum of five times across six points. Results: The method demonstrated precision with relative standard deviations ranging from 3.5% to 19.0%, accuracy for endotoxin recovery between 94.0% and 134.0%, and linearity across the concentration range of 0.05 to 5 EU/mL for the three sera. The detection and quantification limits were established at 0.05 EU/mL. Conclusions: The results confirm that the rFC method provides accurate, precise, specific, and linear quantification of endotoxins in hyperimmune sera within the range of 0.05 to 5 EU/mL at 1:100 dilution. However, for samples spiked with 10 EU/mL (1:100 dilution), the method did not meet the compendial criteria.